butyrophilin like 9Genealiases: BTN3 · BTN8 · VDLS1900
Q-omics provides the consensus-scored BTNL9 profile across patient tissues and cancer cell-line models. BTNL9 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BTNL9 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, BTNL9 RNA expression shows 18,704 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRC, LUAD, and CCRCC as cancer lineages where BTNL9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTNL9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTNL9 survival associations across molecular data types. BTNL9 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTNL9 RNA expression–survival associations across cancer types. High BTNL9 expression shows unfavorable associations in ACC and UVM, but favorable associations in KIRC, LIHC, PAAD and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BTNL9 RNA expression.
This table summarizes BTNL9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BTNL9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTNL9 shows lower tumor expression in LUAD, BLCA, LUSC and KIRP and higher tumor expression in KIRC and COAD. The LUAD box plot shows higher BTNL9 RNA expression in normal versus tumor tissue (log2 FC = −4.068, t-test p < 0.001).
This table shows molecular features associated with BTNL9 in patient tissues and cancer cell lines. In patient samples, BTNL9 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, BTNL9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
